The result only means something once the pattern fits. In axial spondyloarthritis, 85 to 90% of patients carry HLA-B27, against 6 to 8% of the general population 1 2. In a 30-year-old whose back pain started two years ago, wakes them at 4am, and eases with movement, a positive pushes the diagnosis across the line. In a 55-year-old with mechanical pain that eases with rest, the same positive is almost certainly a coincidence.
A negative does not clear you. About one in ten patients with the disease test negative, more so in women and in Black and East Asian patients 3 4. When the gene test cannot settle it, an MRI of the joints where the spine meets the pelvis usually can. The gene is roughly a fifth of the inherited risk; other genes carry the rest 5 6.
Order it only if the back pain looks inflammatory.
It's a single blood draw, no fasting, results in a few days, and done once it's yours for life. Labs report only positive or negative; the subtypes aren't part of routine reporting 7.
What a positive buys the right patient. First-line treatment is the same anti-inflammatory drug class whether the test is positive or negative; a positive can speed access to biologic therapy when the MRI is ambiguous 8 9.
- Weeks: on a full NSAID dose, the morning stiffness that took an hour to walk off shortens; the 4am wake breaks first.
- Months: if NSAIDs aren't enough, TNF or IL-17 blockers give major relief to 40 to 60% of patients within twelve weeks 4.
- Years: the diagnostic delay that averages five to ten years is the real cost of not testing when the pattern fits 10.
Symptom-free relatives asking to be tested: don't. A positive raises their risk to roughly 10 to 20%, but most still never get the disease, a negative doesn't clear them, and nothing prevents it in carriers 11. Teach them the inflammatory pattern instead, and refer if it appears.
The fine print — when to skip it, and what people get wrong
A positive is not a diagnosis: lifetime risk given a positive test and no affected relative is about one to two percent 11 12. A negative does not rule it out, least of all in women and in patients of African, Hispanic, or East Asian ancestry 4.
The common failure is ordering it on mechanical pain that started after 45; a positive there is a coincidence that misleads every clinician who reads the chart after. The mirror failure is calling a negative definitive when the history fits, which delays women most 10.
- 1Rudwaleit M, van der Heijde D, Landewé R, et al. (2009). The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the Rheumatic Diseases. link
- 2Sieper J, Rudwaleit M, Baraliakos X, et al. (2009). The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Annals of the Rheumatic Diseases. link
- 3Reveille JD, Hirsch R, Dillon CF, et al. (2012). The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis & Rheumatism. link
- 4Sieper J, Poddubnyy D (2017). Axial spondyloarthritis. The Lancet. link
- 5Brown MA, Kennedy LG, MacGregor AJ, et al. (1997). Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis & Rheumatism. link
- 6Cortes A, Hadler J, Pointon JP, et al. (2013). Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature Genetics. link
- 7Khan MA (2017). HLA-B27 and its subtypes in world populations. Current Opinion in Rheumatology. link
- 8Ramiro S, Nikiphorou E, Sepriano A, et al. (2023). ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Annals of the Rheumatic Diseases. link
- 9Ward MM, Deodhar A, Gensler LS, et al. (2019). 2019 Update of the American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis & Rheumatology. link
- 10Sykes MP, Doll H, Sengupta R, Gaffney K (2015). Delay to diagnosis in axial spondyloarthritis: are we improving in the UK? Rheumatology (Oxford). link
- 11van der Linden SM, Valkenburg HA, de Jongh BM, Cats A (1984). The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis & Rheumatism. link
- 12Costantino F, Talpin A, Said-Nahal R, et al. (2015). Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort. Annals of the Rheumatic Diseases. link
დაკავშირებული სახელმძღვანელოში (7)
- — This gene flags inflammatory back pain — the kind hiding among people told they just have a bad back.
- — If back pain started young, wakes you at night, and eases with movement, it may be inflammatory — not the disc bulge on your scan.
- — HLA-B27 is a good example of a gene test that helps only in the right clinical context.
- — Both are single-gene HLA tests, valid for life — but each only matters in its specific clinical setting.
- — Another HLA gene test that's only useful for the right clinical picture — here, celiac.
- — A joint or eye that flares with your gut points to spondyloarthritis — the HLA-B27 gene often travels with inflammatory bowel disease.
- — If morning stiffness runs over an hour and a daily routine never touches it, the cause may be inflammatory, not mechanical.
HLA-B27 Testing
Roughly $50–200 out of pocket; usually $0–50 in-network with rheumatology referral. One-time test.
Single blood draw, no prep, no fasting. The harder effort is finding the right indication for ordering it.
Decades of cohort data, two major guideline frameworks (ASAS-EULAR, ACR/SAA/SPARTAN) endorse use in the inflammatory-back-pain workup (Rudwaleit 2009, Ward 2019, Ramiro 2023). Performance metrics well characterised: PLR ~9 in Caucasian cohorts.
Indirect but real: in symptomatic patients, a positive result shortcuts diagnostic delay (mean 5–10 years in axSpA per Sykes 2015) and unlocks effective therapy weeks-to-months sooner, restoring day-to-day function.
Chronic inflammatory back pain is energy-draining; the test accelerates treatment access in B27-positive symptomatic patients, indirectly restoring vitality via NSAID and biologic response (Ramiro 2023).
Inflammatory back pain wakes patients in the second half of the night — a hallmark feature; effective treatment after diagnosis restores sleep architecture. Effect is mediated, not direct.
Diagnostic clarity is a real psychological outcome for patients who have been told their pain has no organic basis; chronic undiagnosed pain carries substantial depression/anxiety comorbidity (Sieper 2017).
Mild mortality elevation in untreated axSpA (cardiovascular and respiratory comorbidity from chronic inflammation); appropriate testing contributes only indirectly via earlier disease control.
Modest indirect effect via reduced pain burden and resolved diagnostic uncertainty; not a direct cognitive intervention.